Trial · NCT07899827
Studying Different Ways of Using Oral Nicotine Pouches to Understand the Effect on Nicotine Delivery, Appeal, and Side Effects Among Adult Cigarette Smokers
NCT07899827, Not applicable, Not yet recruiting, Ohio State University Comprehensive Cancer Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Studying Different Ways of Using Oral Nicotine Pouches to Understand the Effect on Nicotine Delivery, Appeal, and Side Effects Among Adult Cigarette Smokers. Trials, record NCT07899827. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899827
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Studying Different Ways of Using Oral Nicotine Pouches to Understand the Effect on Nicotine Delivery, Appeal, and Side Effects Among Adult Cigarette Smokers
- NCT number
- NCT07899827
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Biospecimen Collection, Oral nicotine pouches, Oral nicotine pouches, Oral nicotine pouches, Oral nicotine pouches, Survey Administration
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plasma Nicotine Pharmacokinetics (Cmax) | At laboratory visits 2, 3, and 4, assessed up to 1 month | The maximum nicotine concentration observed in the plasma samples for each participant. |
| Primary | Plasma Nicotine Pharmacokinetics (Tmax) | At laboratory visits 2, 3, and 4, assessed up to 1 month | The time at which the maximum nicotine concentration is observed in the plasma samples for each participant. |
| Primary | Plasma Nicotine Pharmacokinetics (AUC_0-90) | At laboratory visits 2, 3, and 4, assessed up to 1 month | Area under the curve (AUC) of plasma nicotine levels from minute 0 to 90 for each participant. |
| Primary | Product Liking | At laboratory visits 2, 3, and 4, assessed up to 1 month | Participants will rate appeal (e.g., liking, disliking) on Visual Analogue Scales (range, 0-100). Higher scores indicate a greater degree of liking/disliking. |
| Primary | Product Appeal (mCEQ) | At laboratory visits 2, 3, and 4, assessed up to 1 month | 12-item modified Cigarette Evaluation Questionnaire (mCEQ) completed following ONP self-administration to assess subjective responses to the ONPs. The 12-item mCEQ includes five subscales: Satisfaction, Psychological Reward, Aversion, Enjoyment of Respiratory Tract Sensations, and Craving Reduction, with items rated from 1 (not at all) to 7 (extremely likely). Scores for each subscale are calculated as the mean of the individual item responses or the single item. Higher scores indicate greater intensity on that scale. |
| Primary | Behavioral Economic Demand | At laboratory visits 2, 3, and 4, assessed up to 1 month | After product use, participants will complete a purchase task to assess demand indices including demand elasticity. |
| Primary | Craving Relief (QSU) | At laboratory visits 2, 3, and 4, assessed up to 1 month | Urges/craving will be measured using a modified version of the Tiffany-Drobes Questionnaire of Smoking Urges: Brief Form (QSU). This is a 10-item measure where participants rate items on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). Similar to previous studies, the investigators will collapse the items into two previously identified factors (Factor 1: strong desire and intention to use; Factor 2: anticipation of relief from withdrawal symptoms). Scores are calculated by summing the items and range from 5 to 35 for each of the factors with higher scores indicating greater craving. |
| Primary | Relief of Withdrawal Symptoms (MNWS) | At laboratory visits 2, 3, and 4, assessed up to 1 month | Nicotine withdrawal relief will be measured by the Minnesota Nicotine Withdraw Scale (MNWS). The MNWS asks users how much they are currently feeling certain nicotine withdraw symptoms on a scale of None (0), Slight, Moderate, Mild, or Severe (4). This measure assesses smoking craving, anger/irritability, anxiety, depressed mood, restlessness/difficulty concentrating, increased appetite, sleep problems, and somatic symptoms (nausea, constipation, sore throat, dizziness, coughing). MNWS is the sum of 8 items with scores ranging from 0 to 32 . |
| Primary | Intensity of Sensory Attributes (gLMS) | At laboratory visits 2, 3, and 4, assessed up to 1 month | 5-item self-report measure completed following ONP administration, using the general Labeled Magnitude Scale (gLMS). Scores range from 0 (no sensation) to 100 (strongest imaginable) with higher scores indicating a greater sensation intensity. |
| Primary | Behavioral Intentions | At laboratory visits 2, 3, and 4, assessed up to 1 month | Intentions to use the product again using the respective topography, purchase the product for personal use if required to use the topography, and use the product regularly following the topography. Self-report measure on a 7-point scale. Ratings range from 1 (extremely unlikely) to 7 (extremely likely) with higher scores indicating a higher likelihood of continuing to use the product. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R21DA067197 | Exploring the effects of oral nicotine pouch use topography on measured abuse liability and adverse effects | Keller-Hamilton, Brittney L | OHIO STATE UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Purchase Task | Primary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899827
GET https://conductscience.org/api/trials/v1/NCT07899827/registered